Austin, TX, USA, July 16, 2025 (GLOBE NEWSWIRE) — Custom Market Insights has published a new research report titled “Ultomiris Drug Market Size, Trends and Insights By Indication (Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD)), By End-use (Adult, Pediatric), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region – Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034“ in its research database.
“According to the latest research study, the demand of the global Ultomiris Drug Market size & share was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach a value of around USD 64.12 Billion by 2034, at a compound annual growth rate (CAGR) of about 31.52% during the forecast period 2025 to 2034.”
Click Here to Access a Free Sample Report of the Global Ultomiris Drug Market @ https://www.custommarketinsights.com/request-for-free-sample/?reportid=70951
Overview
As per the industry experts at CMI, the global ultomiris drug market will witness a whopping CAGR between 2025 and 2034. This could be attributed to the rise in demand for various long-acting treatments for rare disorders, especially paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). North America holds the largest market share due to speedy adoption of ultomiris drug by the U.S. and Canada. Hospital pharmacies dominate as far as distribution channels are concerned.
Key Trends & Drivers
- Long-Acting Treatment Preference to Spell Growth: Ultomiris does offer a long-acting dosing interval (every 8 weeks), which enhances patient convenience and compliance as compared to the shorter-acting alternatives. Ultomiris is also known for demonstrating robust clinical performance along with a well-established safety profile.
Request a Customized Copy of the Ultomiris Drug Market Report @ https://www.custommarketinsights.com/request-for-customization/?reportid=70951
- Approval by Regulatory Bodies to Catalyze Growth: The U.S. FDA had approved ultomiris for adults suffering from gMG in the year 2022. Since then, the drug has strengthened its position in the neurology sector. The FDA also conducted a review on priority in March 2024 for ultomiris in NMOSD. These approvals and reviews are bound to take the ultomiris market to the next level in the forecast period.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 5.47 Billion |
| Projected Market Size in 2034 | USD 64.12 Billion |
| Market Size in 2024 | USD 4.16 Billion |
| CAGR Growth Rate | 31.52% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Prominent Players | AstraZeneca, Xencor Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, Others, and Others |
| Key Segment | By Indication, End-use, Distribution Channel and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
(A free sample of the Ultomiris Drug report is available upon request; please contact us for more information.)
Our Free Sample Report Consists of the following:
- Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report.
- The COVID-19 Pandemic Outbreak Impact Analysis is included in the package.
- About 220+ Pages Research Report (Including Recent Research)
- Provide detailed chapter-by-chapter guidance on the Request.
- Updated Regional …